RC-RET

Research Profile

Overview

Retatrutide is an investigational, single-peptide compound engineered to activate three hormone receptors involved in metabolic regulation: the glucose-dependent insulinotropic polypeptide receptor, glucagon-like peptide-1 receptor, and glucagon receptor.

This combination distinguishes retatrutide from single-receptor GLP-1 agonists and dual GIP/GLP-1 receptor agonists. Researchers are studying whether coordinated activity across all three pathways can influence appetite signaling, glucose homeostasis, energy expenditure, lipid metabolism, and body composition more broadly than compounds that act through fewer receptors.

Retatrutide remains investigational and has not been approved for general public use. Its efficacy, long-term safety, and potential applications continue to be evaluated through clinical development programs.

Scientific Background

Retatrutide was developed under the identifier LY3437943 as a single molecular structure capable of activating the GIP, GLP-1, and glucagon receptors.

Early laboratory research examined whether the three-receptor design could combine the appetite- and glucose-related activity associated with incretin signaling with the effects of glucagon-receptor activity on energy and nutrient metabolism. The relative contribution of each receptor to the compound’s overall effects in humans remains an active area of investigation.

A Phase 1b study in participants with type 2 diabetes evaluated repeated exposure, pharmacokinetics, tolerability, glucose-related outcomes, and changes in body weight. The results supported progression into larger Phase 2 studies involving metabolic function and obesity-related research.

Mechanism of Action

Retatrutide is commonly described as a triple receptor agonist because one peptide activates three separate metabolic receptors.

GLP-1 Receptor Activity

GLP-1 receptor signaling is studied for its involvement in:

• Appetite and satiety signaling
• Glucose-dependent insulin secretion
• Post-meal glucose regulation
• Gastric emptying
• Central nervous system regulation of food intake

This pathway is believed to contribute substantially to the appetite- and glucose-related findings observed with incretin-based compounds.

GIP Receptor Activity

GIP receptor signaling is associated with nutrient-responsive metabolic activity. Researchers study this pathway for its potential involvement in:

• Glucose-dependent insulin signaling
• Adipose-tissue metabolism
• Nutrient handling
• Interactions with GLP-1 receptor activity
• Metabolic flexibility

The effects of GIP receptor activation can depend on the metabolic state and on the activity of other receptors being stimulated at the same time.

Glucagon Receptor Activity

Glucagon receptor signaling is involved in hepatic glucose production, lipid handling, amino-acid metabolism, and energy expenditure.

When incorporated into a multi-receptor compound, glucagon-receptor activity is being studied to determine whether it can support increased energy use and reductions in fat mass while the GIP and GLP-1 pathways help regulate appetite and glucose-related responses.

Combined Receptor Activity

The scientific interest in retatrutide centers on the interaction of all three pathways rather than on any receptor acting independently.

The proposed research model is that:

• GLP-1 activity influences appetite and glucose regulation.
• GIP activity complements incretin and nutrient-related signaling.
• Glucagon activity contributes to energy expenditure and substrate metabolism.

The precise contribution of each pathway—and the degree to which they interact synergistically—has not been fully established in humans.

Primary Areas of Scientific Investigation

Body Weight and Body Composition

Retatrutide has been studied for changes in overall body weight, waist circumference, fat mass, and lean mass.

A 48-week Phase 2 obesity trial reported dose-dependent reductions in body weight, with the highest studied dose producing a mean reduction of approximately 24% under the trial’s efficacy analysis. These findings established retatrutide as an important compound in multi-receptor metabolic research.

A later body-composition analysis in participants with type 2 diabetes found that reductions in body weight were primarily associated with reductions in fat mass. The proportion of lean mass lost relative to total weight loss was reported as broadly similar to that observed with other obesity interventions.

Appetite and Eating Behavior

Researchers are examining how the GLP-1 and GIP components of retatrutide influence hunger, satiety, food intake, and eating behavior.

Participant interviews conducted during the Phase 2 obesity program reported changes in appetite and eating patterns, although these subjective findings require interpretation alongside controlled clinical measurements.

Glucose Homeostasis

Retatrutide has been evaluated in participants with type 2 diabetes for changes in:

• Glycated hemoglobin
• Fasting and daily glucose
• Insulin-related responses
• Body weight
• Broader metabolic markers

Phase 1b and Phase 2 studies reported improvements in glycemic measurements alongside reductions in body weight, supporting continued investigation in larger clinical programs.

Energy Expenditure and Lipid Metabolism

The glucagon-receptor component makes energy expenditure and lipid metabolism particularly important areas of retatrutide research.

Investigators are examining whether triple-receptor activity changes how stored nutrients are mobilized, how lipids circulate in the bloodstream, and how the body balances energy intake with energy expenditure. The extent to which these findings are directly caused by glucagon-receptor activity rather than secondary to weight reduction remains under study.

Liver Fat and Metabolic Liver Research

A Phase 2 substudy evaluated retatrutide in participants with elevated liver fat associated with metabolic dysfunction.

Researchers reported substantial reductions in measured liver fat among several retatrutide groups. These findings support further study of triple-receptor agonism in metabolic dysfunction-associated steatotic liver disease, but they do not establish an approved indication.

Cardiometabolic Research

Retatrutide research programs are also examining measurements such as:

• Waist circumference
• Triglycerides
• Non-HDL cholesterol
• Blood pressure
• Inflammatory markers
• Cardiovascular outcomes
• Renal outcomes

Changes in these measurements may be influenced by weight reduction, direct receptor activity, or a combination of mechanisms. Dedicated outcome trials are needed to determine whether changes in biomarkers translate into long-term clinical outcomes.

Research Findings

Phase 2 Obesity Research

In the published 48-week Phase 2 obesity study, retatrutide produced dose-dependent reductions in body weight. The study also evaluated waist circumference, metabolic markers, safety, and tolerability.

The trial provided peer-reviewed evidence supporting the continued development of the triple-receptor approach, while also establishing the need for larger and longer studies.

Phase 2 Type 2 Diabetes Research

In participants with type 2 diabetes, Phase 2 research reported improvements in glycated hemoglobin and reductions in body weight.

These results helped guide the dose selection and design of the subsequent Phase 3 development program.

Phase 3 Development Update

In May 2026, Lilly reported topline results from the Phase 3 TRIUMPH-1 obesity trial. Under the efficacy analysis, the highest studied dose was associated with a mean body-weight reduction of 28.3% at 80 weeks. A prespecified extension involving a subset of participants with a higher starting body-mass index reported a mean reduction of 30.3% at 104 weeks.

These figures were manufacturer-reported topline results at the time this section was prepared. Full interpretation should rely on detailed peer-reviewed publication, including complete methods, statistical analyses, discontinuation data, and adverse-event reporting.

Safety and Research Limitations

Across early and later clinical studies, the most frequently reported adverse events were gastrointestinal, including nausea, diarrhea, constipation, and vomiting. Adverse events and discontinuation rates varied according to dose and study design.

Several limitations remain important:

• Retatrutide is still investigational.
• Long-term safety has not been fully characterized.
• Rare adverse events may not be detected until much larger populations are studied.
• The contribution of each individual receptor remains incompletely understood.
• Changes in biomarkers do not automatically establish improved long-term health outcomes.
• Manufacturer-reported topline findings require confirmation through complete peer-reviewed publication.

The information on this page should not be interpreted as evidence of regulatory approval, instructions for administration, or a recommendation for human use.

Peptidea Product Information

RC-RET is the Peptidea product code used to identify retatrutide within the Research Library.

Because available strengths, packaging, storage instructions, and product configurations may change, readers should refer to the current RC-RET product listing on Peptidea.net rather than relying on fixed operational details printed in the handbook.

No QR code or category-page link will be included until the final Peptidea website structure and destination pages have been established and tested.

Related Research Compounds

Key Research Takeaways

Retatrutide is:

• A single peptide with activity at three metabolic receptors.
• Investigated for body composition, appetite, glucose regulation, lipid metabolism, and energy balance.
• Supported by published Phase 1 and Phase 2 research.
• The subject of an extensive Phase 3 development program.
• Still investigational and not approved for general public use.
• A compound whose long-term safety and receptor-specific effects remain under investigation.

Selected Scientific References

1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof. Cell Metabolism. 2022.
2. Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b trial. The Lancet. 2022.
3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. The New England Journal of Medicine. 2023.
4. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. 2023.
5. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. 2024.
6. Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2025.